Status:
COMPLETED
Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients
Lead Sponsor:
Novartis Pharmaceuticals
Collaborating Sponsors:
Tanabe Pharma Corporation
Conditions:
Renal Transplantation
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This study will evaluate the safety and efficacy of FTY720 combined with cyclosporine and corticosteroids in patients receiving a kidney transplant.
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patients who have completed the 12 Month visit of the Core trial either on or off study drug.
- Female capable of becoming pregnant are required to have a medically approved method of birth control until 3 Month after study medication was stopped.
- Exclusion Criteria
- \- None
Exclusion
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
255 Patients enrolled
Trial Details
Trial ID
NCT00239798
Start Date
November 1 2004
Last Update
February 23 2017
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.